2024.06.13
On 13 June 2024, QuantumPharm Inc. ("QuantumPharm" or the "Company"; Stock Code: 2228.HK) was listed on the Main Board of the Hong Kong Stock Exchange. QuantumPharm is the first stock to be listed under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hong Kong Stock Exchange.
QuantumPharm is an innovative quantum physics-based, AI-powered and robotics-driven innovative R&D platform. It provides drug and materials science R&D solutions and services to global and domestic companies in the pharmaceutical and materials science industries (including agrotechnology, energy and novel chemicals, and cosmetics).
QuantumPharm has provided services to and collaborated with many biotechnology and pharmaceutical global corporations including Pfizer, Jonsson, Merck KGaA (Darmstadt, Germany), Chiatai Tianqing (China) and Daewoo Pharmaceutical (Korea). According to Frost & Sullivan, as of 29 May 2024, the Company has provided services to more than 300 biotechnology and pharmaceutical companies and research institutes globally, including 16 of the world's top 20 biotechnology and pharmaceutical companies (in terms of 2022 revenue). QuantumPharm’s advanced technology has attracted private equity and strategic investors such as Sequoia, Mirae Asset, Google, Tencent, ChinaLife Chengda, and 5Y Capital. As of 31 December 2023, QuantumPharm had raised approximately US$732 million through private equity financing from a number of financial and strategic investors, ranking first among all AI-enabled drug R&D companies in the world in terms of the total amount of funds raised through private equity financing according to Frost & Sullivan.
JunHe acted as the PRC legal advisor to the sole sponsor and the underwriters in the listing of QuantumPharm under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hong Kong Stock Exchange. JunHe’s team assisted the sole sponsor in conducting legal due diligence, participating in communications and interviews with the regulators, reviewing and revising the PRC legal opinion and data compliance memorandum, and reviewing and revising the PRC legal opinions, data compliance memorandum, prospectus and other relevant application and offering documents. They assisted and closely co-operated with various intermediaries in preparing and issuing a full set of legal documents for filing with the China Securities Regulatory Commission for overseas listing and assisted various parties to respond to feedback from the China Securities Regulatory Commission, the Hong Kong Securities Regulatory Commission and the Hong Kong Stock Exchange on their concerns under the PRC domestic laws.
JunHe provided a series of high-quality, rigorous and efficient legal services for the issues under the PRC domestic laws that are involved in the listing under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hong Kong Stock Exchange, which ultimately helped QuantumPharm become “Hong Kong’s First 18C Stock".
The lead partners in this project were Mr. TAO, Xudong, Mr. LIN, Jiayu (Paul), Mr. ZHANG, Jianwei and Ms. ZHANG, Zhijin (Jean), and the core partner was Mr. YI, Yisong. Ms. DONG, Xiao (Marissa) provided significant support on all data compliance matters.
